Levoleucovorin Treatment for Autism - Richard Frye MD PhD, Aprofol @Sychrony2022

Autism Spectrum Disorder (ASD) affects about 1 in 44 children in the USA with effective treatments lacking. ASD is associated with several disruptions in folate metabolism, including a unique disruption in the transport of folate into the brain due to folate receptor alpha autoantibodies (FRAAs).

Initially Phase II controlled clinical trials have shown that D,L- leucovorin, a reduced form of folate, can circumvent this blockage in folate transport and improve ASD symptoms, especially in those individuals positive for FRAAs. Additional Phase II multicenter clinical trials with the L-isomer of leucovorin, levoleucovorin manufactured by AprofolAG (Steinegg, Switzerland), in both preschool and school aged children with ASD are ongoing to confirm initial findings and identify additional biomarkers to predict response to treatment.

This talk discusses the previous and ongoing studies showing the effectiveness of leucovorin in children with ASD and other neurodevelopmental disorders such as Cerebral Folate Deficiency as well as discuss known and novel biomarkers under development.


🎥 This talk was part of Synchrony 2022 Online Symposium - 'From Bench to Biopharma', organised by the The BRAIN Foundation

🎥 For more Synchrony 2022 talks and highlights:
   • Synchrony Symposium 2022 - From Bench To B...  


🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

Synchrony https://synchronysymposium.com/ is the first and only international symposium on translational research in #autism, that brings together academia, #biotech, pharmaceutical companies and #venture partners from around the world with the mission to improve health and quality of life of people with #autismspectrumdisorder.

🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

The BRAIN Foundation https://brainfoundation.org/ is a 501c(3) non-profit. The founders of BRAIN envision a world where every child and adult on the autism spectrum is healthy, participates fully in education and employment, and has a better quality of life. It aims to catalyze research that results in evidence-based interventions for the disabilities associated with autism, and also results in better medical standard of care.

To accomplish this, it funds impactful research through #philanthropy and our network of partners in the venture, corporate, and grassroots community.